NASDAQ:ABMD Abiomed (ABMD) Stock Price, News & Analysis → The new masters of energy (From Porter & Company) (Ad) Free ABMD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$381.02▼$381.0250-Day Range$377.20▼$381.3052-Week Range$219.85▼$381.99Volume258 shsAverage Volume611,028 shsMarket Capitalization$17.18 billionP/E Ratio65.47Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Abiomed alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Abiomed Stock (NASDAQ:ABMD)Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… ABMD Stock News HeadlinesApril 17, 2024 | finance.yahoo.com‘We think in decades’: J&J’s $30B spending spree may not be overApril 3, 2024 | bizjournals.comFDA issues alert on Abiomed heart pump associated with 49 deathsApril 1, 2024 | msn.comAbiomed Heart Pumps Linked to 49 DeathsMarch 21, 2024 | yahoo.comUS FDA classifies corrections to instructions for Abiomed's blood pumps as most seriousMarch 21, 2024 | reuters.comUS FDA classifies recall of Abiomed's blood pumps as most seriousMarch 19, 2024 | forbes.comWill Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs Of $185?January 16, 2024 | finance.yahoo.comAbiomed Inc's Pipeline Analysis for 2023 Reveals Clinical Advancement in Circulatory Support TechnologyOctober 23, 2023 | finance.yahoo.comAbiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT SymposiumOctober 14, 2023 | bizjournals.comFDA warns Abiomed over device classificationJune 7, 2023 | msn.comJ&J's Abiomed unit recalls Impella 5.5 heart pumps over safety concernsMay 1, 2023 | uk.finance.yahoo.comAbiomed, Inc. (ABMD) stock price, news, quote & history – Yahoo FinanceMarch 21, 2023 | stocknews.comWant to Retire a Millionaire? 2 Stocks to Buy NowMarch 17, 2023 | stocknews.com3 Stocks That Could Deliver Healthy Returns in 2023March 13, 2023 | stocknews.comThis Big Pharma Stock Is a Clear Buy in 2023March 12, 2023 | uk.finance.yahoo.comAbiomed, Inc. (ABMD) stock historical prices & data – Yahoo FinanceMarch 10, 2023 | stocknews.com3 Powerhouse Stocks to Buy in 2023March 6, 2023 | stocknews.com3 Hot Dividend Stocks to Buy Now and Hold ForeverMarch 4, 2023 | finance.yahoo.comAbiomed, Inc. (ABMD) Stock Historical Prices & Data - Yahoo FinanceMarch 2, 2023 | stocknews.com2 No-Brainer Warren Buffett Stocks to Buy in 2023March 1, 2023 | stocknews.com3 S&P 500 Stocks to Buy If You Like WinningFebruary 28, 2023 | stocknews.com3 Stocks to Help Grow Your Portfolio Over the Next DecadeDecember 22, 2022 | finance.yahoo.com3 Reasons to Retain Abiomed (ABMD) Stock in Your PortfolioDecember 21, 2022 | finance.yahoo.comFDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical TrialDecember 13, 2022 | finance.yahoo.com10 Best Performing Stocks in NovemberDecember 8, 2022 | finance.yahoo.comThis Monster Dividend Stock Isn't Done GrowingSee More Headlines Receive ABMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today6/08/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ABMD CUSIP00365410 CIK815094 Webwww.abiomed.com Phone(978) 646-1400Fax978-777-8411Employees2,003Year Founded1981Profitability EPS (Most Recent Fiscal Year)$5.82 Trailing P/E Ratio65.47 Forward P/E Ratio83.19 P/E Growth3.33Net Income$136.51 million Net Margins24.84% Pretax Margin31.76% Return on Equity14.77% Return on Assets13.32% Debt Debt-to-Equity RatioN/A Current Ratio7.93 Quick Ratio7.17 Sales & Book Value Annual Sales$1.03 billion Price / Sales16.65 Cash Flow$5.09 per share Price / Cash Flow74.88 Book Value$33.03 per share Price / Book11.54Miscellaneous Outstanding Shares45,091,000Free Float43,964,000Market Cap$17.18 billion OptionableOptionable Beta1.40 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Michael R. Minogue (Age 56)Chairman, CEO & Pres Comp: $3.04MMr. Todd A. Trapp (Age 52)Exec. VP & CFO Comp: $914.93kMr. Marc A. Began (Age 56)Exec. VP, Gen. Counsel & Sec. Comp: $818.64kMr. Andrew J. Greenfield (Age 50)Exec. VP & Chief Commercial Officer Comp: $804.95kDr. David M. Weber Ph.D. (Age 62)Scientific & Technology Advisor Comp: $1.02MMr. Matthew T. Plano (Age 58)Exec. VP of Global Operations & Integration Dr. Thorsten Siess Ph.D.Exec. VP & Chief Technology OfficerMs. Ingrid Goldberg WardDirector of Investor RelationsSarah KarrCommunications Mang.Mr. Michael G. Howley (Age 59)VP & GM of Global Sales More ExecutivesKey CompetitorsHill-RomNYSE:HRCiRhythm TechnologiesNASDAQ:IRTCNovoCureNASDAQ:NVCRNevroNYSE:NVROEdwards LifesciencesNYSE:EWView All Competitors Should I Buy Abiomed Stock? ABMD Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Abiomed, Inc.: Abiomed, Inc. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance. The company's innovative heart pump technology, such as the latest version of their heart pump device, has been well-received in the market, positioning them as a leader in the medical device industry. Abiomed's stock price has been steadily increasing, reflecting positive investor sentiment and potential for further growth. With a solid balance sheet and healthy cash reserves, Abiomed is well-equipped to weather any market uncertainties and invest in future growth opportunities. The company's strong research and development pipeline, including advancements in cardiac care technology, indicates potential for sustained growth and market expansion. Cons Investors should be bearish about investing in Abiomed, Inc. for these reasons: Despite its growth potential, Abiomed, Inc. operates in a highly competitive market with other major players, which could impact its market share and profitability. Fluctuations in healthcare regulations and reimbursement policies could affect Abiomed's revenue and profitability, posing a risk to investors. As a medical device company, Abiomed is subject to regulatory approvals and compliance requirements, which could lead to delays in product launches and impact financial performance. Market volatility and economic uncertainties may impact the demand for Abiomed's products, affecting its sales and revenue growth. Investing in a specialized industry like medical devices carries inherent risks, including technological advancements by competitors and changing healthcare trends that could impact Abiomed's market position. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these Abiomed pros and cons to contact@marketbeat.com. ABMD Stock Analysis - Frequently Asked Questions How were Abiomed's earnings last quarter? Abiomed, Inc. (NASDAQ:ABMD) issued its quarterly earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $0.98 by $0.05. The medical equipment provider earned $248.10 million during the quarter, compared to analysts' expectations of $248.06 million. Abiomed had a net margin of 24.84% and a trailing twelve-month return on equity of 14.77%. The firm's revenue was up 18.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.01 EPS. Read the conference call transcript. What is Michael R. Minogue's approval rating as Abiomed's CEO? 96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees. What other stocks do shareholders of Abiomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM). Does Abiomed have any subsidiaries? The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.Read More This page (NASDAQ:ABMD) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abiomed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abiomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.